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Abstract
Background: There is strong evidence that post-exposure prophylaxis (PEP) with antiretroviral drugs in the timely
management of occupational exposures sustained by healthcare workers decreases the risk of HIV infection and
PEP is now widely used. Antiretroviral drugs have well documented toxicities and produce adverse events in
patients living with HIV/AIDS. In the era of “highly active antiretroviral therapy”, non-adherence to treatment has
been closely linked to the occurrence of adverse events in HIV patients and this ultimately influences treatment
success but the influence of adverse events on adherence during PEP is less well studied.
Methods: Following the introduction of a HIV post-exposure prophylaxis program in the Korle-Bu Teaching Hospital
in January 2005, the incidence of adverse events and adherence were documented in occupationally-exposed
healthcare workers (HCWs) and healthcare students (HCSs). Cohort event monitoring was used in following-up on
exposed HCWs/HCSs for the two study outcomes; adverse events and adherence. All adverse events reported were
grouped by MedDRA system organ classification and then by preferred term according to prophylaxis regimen.
Adherence was determined by the completion of prophylaxis schedule. Cox proportional regression analysis was
applied to determine the factors associated with the cohort study outcomes. Differences in frequencies were tested
using the Chi square test and p < 0.05 was considered statistically significant.
(Continued on next page)
* Correspondence: r_niiatetteh@yahoo.com
1Utrecht Institute for Pharmaceutical Sciences, Utrecht University,
Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
2Pharmacy Department, Korle-Bu Teaching Hospital, P.O. Box KB 77, Korle-Bu,
Accra, Ghana
Full list of author information is available at the end of the article
© 2015 Tetteh et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Tetteh et al. BMC Public Health  (2015) 15:573 
DOI 10.1186/s12889-015-1928-6
(Continued from previous page)
Results: A total of 228 exposed HCWs/HCSs were followed up during the study, made up of 101 exposed HCWs/
HCSs administered lamivudine/zidovudine (3TC/AZT) for 3 days; 75 exposed HCWs/HCSs administered lamivudine/
zidovudine (3TC/AZT) for 28 days; and 52 exposed HCWs/HCSs administered lamivudine/zidovudine/lopinavir-
ritonavir (3TC/AZT/LPV-RTV) for 28 days. The frequency of adverse events was 28 % (n = 28) in exposed HCWs/HCSs
administered 3TC/AZT for 3 days, 91 % (n = 68) in exposed HCWs/HCSs administered 3TC/AZT for 28 days and 96 %
(n = 50) in exposed HCWs/HCSs administered 3TC/AZT/LPV-RTV for 28 days. Nausea was the most commonly
reported adverse events in all three regimens. Adherence was complete in all exposed HCWs/HCSs administered
3TC/AZT for 3days, 56 % (n = 42) in exposed HCWs/HCSs administered 3TC/AZT for 28 days and 62 % (n = 32) in
exposed HCWs/HCSs administered 3TC/AZT/LPV-RTV for 28 days. In the Cox regression multi-variate analysis,
exposed HCWs/HCSs administered 3TC/AZT for 3 days were 70 % less likely to report adverse events compared with
exposed HCWs/HCSs administered 3TC/AZT for 28 days (Adjusted HR = 0.30 [95 % CI, 0.18-0.48], p < 0.001). Exposed
HCWs/HCSs administered 3TC/AZT for 3 days were 75 % more likely to adhere to the schedule compared with
exposed HCWs/HCSs administered 3TC/AZT for 28 days (Adjusted HR = 1.75 [95 % CI, 1.16-2.66], p = 0.008).
Conclusion: The intolerance to adverse events was cited as the sole reason for truncating PEP, thereby indicating the
need for adequate, appropriate and effective counselling, education, active follow-up (possibly through mobile /phone
contact) and management of adverse events. Education on the need to complete PEP schedule (especially for exposed
HCWs/HCSs on 28-day schedule) can lead to increased adherence, which is very critical in minimizing the risk of HIV
sero-conversion. The present results also indicate that cohort event monitoring could be an effective pharmacovigi-
lance tool in monitoring adverse events in exposed HCWs/HCSs on HIV post-exposure prophylaxis.
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Background
There is evidence that post-exposure prophylaxis (PEP)
with antiretroviral drugs in the timely management of
occupational exposures sustained by healthcare workers
(HCWs) decreases the risk of HIV infection and this
type of approach is now widely used [1, 2]. A case con-
trol study among HCWs showed that post-exposure use
of zidovudine after percutaneous exposure to HIV in-
fected blood was associated with a reduction of the risk
of HIV infection by about 81 % [3, 4].
In HIV-infected patients, combination regimens have
proven to be superior to monotherapy regimens in redu-
cing viral load [5, 6]. Thus, a combination of drugs with
activity at different stages in the viral replication cycle the-
oretically may offer a greater preventative effect in PEP,
particularly for occupational exposures. This is supported
by clinical evidence that the use of dual or triple antiretro-
viral drugs in PEP can prevent sero-conversion by as
much as 80 % [7]. However, speed of thought and action
is crucial as the window of opportunity to prevent sys-
temic viral dissemination is narrow. Based on these find-
ings, the WHO recommended the use of combination
regimens (dual/triple) to prevent HIV sero-conversion in
PEP programs which was adopted and adapted by the Na-
tional HIV/AIDS Control Program (NACP) for use in
Ghana [8]. However, the decision to initiate PEP must take
into account the potential benefit of preventing infection
versus the risk of toxicity from the medications used.
Antiretroviral drugs (ARVs) have well documented
toxicities and produce adverse events in patients living
with HIV/AIDS. These adverse events have been re-
ported in several studies involving cohorts of patients
with incidence rates as high as 54 % being reported in
some instances [9, 10]. In the era of “highly active anti-
retroviral therapy” (HAART), non-adherence to treat-
ment has been closely linked to the occurrence of
adverse events in HIV patients and this ultimately influ-
ences treatment success [11–14]. HAART is also used
for PEP but for a shorter duration of maximally 28 days
compared with HIV patients who are generally on life-
long medication. However, several studies indicate a
higher frequency of reported adverse events in PEP pa-
tients who receive multidrug regimens compared with
HIV positive patients taking similar or same medication
for HIV management [15–22]. This frequency is higher
among PEP patients who received triple therapy com-
pared with those who received dual therapy [15, 21] but
the rate of discontinuation of PEP was not significantly
different between the two PEP therapy groups [21].
With the introduction of HAART, there have been con-
siderable changes in the administered ARV cocktail which
comes along with its own adverse events and adherence
issues. The use of ARVs in PEP has shifted from the ad-
ministration of single-drugs like zidovudine to multi-drug
regimens involving dual or triple therapy with their associ-
ated issues of adverse events and adherence. Very few
studies on adverse events and adherence in exposed
HCWs/HCSs administered PEP has been conducted in
developing countries, hence results from resource-limited
settings like the Korle-Bu Teaching Hospital (KBTH) in
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Accra, Ghana is useful for an effective implementation
and education of HCWs on PEP in these settings. Such
studies also go a long way to aid program design and
national policy in relation to PEP.
The KBTH in Ghana with a workforce of about 1930
HCWs and 3330 healthcare students (HCSs), attends to
over 3000 patients daily and also provides HAART ser-
vices to over 20,000 HIV patients. In 2003, the National
AIDS/STI Control Program (NACP) in Ghana provided
guidelines on the provision of PEP in all sites that offer
clinical care to patients living with HIV including KBTH,
one of the four pilot sites for ART delivery at the time.
KBTH has since then been offering HAART services to
clients regularly.
This study utilizes cohort event monitoring to follow
exposed HCWs/HCSs for adverse events and adherence to
PEP during a PEP service between January 2005 and
December 2010. Cohort-event monitoring (CEM), a pro-
spective and observational cohort study is an adaptation of
prescription-event monitoring and it involves actively
following up on patients within a defined time-frame for
reports of adverse events [23]. CEM employs the technique
of actively collecting adverse events reports from patients,
mostly by mobile phone calls or, in some cases, direct
home visits. Collection of safety data using mobile phones
is very appropriate for resource-limited settings like Ghana
where the penetration of mobile telephony is high.
Methods
Setting
This study was a prospective cohort analysis of HCWs/
HCSs administered PEP at the KBTH in Accra, the
premier tertiary referral hospital in Ghana, during the
period of January 2005 to December 2010. A team of
healthcare professionals made up of medical and phar-
macy personnel were responsible for providing PEP ser-
vice to exposed healthcare workers using an in-house
risk assessment system previously described [24] as well
as guidelines based on the recommendations of the US
Centers for Disease Control and Prevention (CDC) [25].
A risk assessment is done considering the type of injury,
the volume of fluid involved, the type of instrument
involved (e.g. hollow-bore needle, solid needle etc.) the
HIV status of the source patient, the HIV viral load of
the source patient and the circumstances surrounding
the injury (the depth and extent of injury) as per the na-
tional guidelines. This is done on a one-on-one basis for
individuals presenting following an exposure. Based on
the results of the assessment, a decision is made as to
the level of risk of the exposure and the appropriate HIV
PEP to be administered according to local guidelines.
HCWs/HCSs with exposures assessed as high risk were
administered either lamivudine/zidovudine/lopinavir-ri-
tonavir (3TC/AZT/LPV-RTV) (triple therapy) for 28
days or lamivudine/zidovudine (3TC/AZT) (dual ther-
apy) for 28 days. HCWs/HCSs with exposures assessed
as medium or low risk were administered either lamivu-
dine/zidovudine (3TC/AZT) (dual therapy) for 28 days
or lamivudine/zidovudine (3TC/AZT) for 3 days. How-
ever in some exceptional cases, some HCWs/HCSs with
exposures assessed as low/medium risk were adminis-
tered 3TC/AZT/LPV-RTV for 28 days on their insistent
request. Figure 1 outlines the algorithm used in the risk
assessment of exposures.
Data collection
The procedures and criteria for the administration of PEP
and collection of data (age, gender, HIV status of exposure
source, means of exposure, type of exposure, risk assess-
ment, profession, duration of exposure and department
where the HCW/HCS belongs) have been described in a
previous paper [24]. Exposed HCWs/HCSs were adminis-
tered either lamivudine/zidovudine (3TC/AZT) (dual ther-
apy) for 3 or 28 days (depending on the outcome of the risk
assessment made) or lamivudine/zidovudine/lopinavir-rito-
navir (3TC/AZT/LPV-RTV) (triple therapy) for 28 days.
Active follow-up on exposed HCWs/HCSs were for two
outcomes: a) HIV-testing schedule for possible sero-
conversion (at 6 weeks, 3 months and 6 months) and b) ad-
verse events and adherence. Outcome of the follow-up for
HIV-testing schedule has been described previously [24].
Active follow-up for adverse events and adherence to
prophylaxis schedule were performed by trained re-
search assistants through telephone contact on days 3
and 10 after drug dispensing for those on the 3-day
schedule and on days 3, 10, 20, 28 and 35 after drug dis-
pensing for those on the 28 days schedule. In addition to
the active follow-up, exposed HCWs/HCSs were asked
to report events of medical concern (literally “anything
that worries you”) at any time during the follow-up
period, noting especially the following signs; fever, rash,
lymphadenopathy, dark-coloured urine, sore throat and
bruising or bleeding from any part of the body. A struc-
tured questionnaire, interview guide was used to collect
data from exposed HCWs/HCSs. Event data on adverse
events was first recorded according to how the patient
described the event (verbatim) and then reviewed quali-
tatively and coded using the Medical Dictionary for
Regulatory Activities (MedDRA, version 13.1) termin-
ology. All adverse events reported were grouped by
MedDRA system organ classification (SOC) and then by
preferred term (PT) according to prophylaxis regimen. It
is important to note that unlike some CEM studies, the
presence of adverse events prior to treatment initiation
was not undertaken. All adverse events solicited post-
treatment were new events that could conceivably be
associated with PEP though no formal case-causality
assessment was carried out on the individual reports.
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Adherence was determined by the completion of
prophylaxis schedule assessed during the follow-up
period by the use of a questionnaire. Non-adherence
was defined as the inability to complete all the 3 days of
the prophylaxis schedule for exposed HCWs/HCSs on
the 3-day schedule and all the 28 days for exposed
HCWs/HCSs on the 28-day schedule as prescribed.
Data management and analysis
Each exposed HCW/HCS was given a unique study code
which was used in data storage and management relating
to that HCW/HCS. Data were double entered, cleaned and
managed using Microsoft Access (Microsoft Corporation,
Redmond, Washington) and analysed using SPSS version
19 (IBM, Armonk, New York). Data were expressed as fre-
quencies and percentages for categorical variables. Differ-
ences in frequencies and proportions were tested using the
chi square test. The primary outcomes of interest were “ad-
verse events” and “adherence”. Cox proportional regression
analysis was applied to determine the factors associated
with adverse events/adherence and reported as a crude
hazard ratio in the univariate analysis. Variables signifi-
cantly associated with adverse events or adherence in the
univariate analysis (at p < 0.10) were adjusted for in the
multivariate analysis and reported as an adjusted hazard
ratio. P < 0.05 was considered statistically significant.
Ethics
The study was approved by the Ethical and Protocol
Review Committee of the University of Ghana Medical
School [MS-Et/M.6-P.5.3/2009-10].
Results
Exposure information and characteristics of HCWs during
reporting and HIV PEP administration
Results from Fig. 2 indicate that out of a total of 280
HCWs/HCs who reported for the PEP service during
the study period, 145 (51.8 %) exposed HCWs/HCSs
were administered 3TC/AZT for 3 days of which 101
were successfully followed up, 82 (29.3 %) exposed
HCWs/HCSs were administered 3TC/AZT for 28 days
of which 75 exposed HCWs/HCSs were successfully
followed up and 53 (18.9 %) exposed HCWs/HCSs were
administered 3TC/AZT/LPV-RTV for 28 days of which
52 exposed HCWs/HCSs were successfully followed up.
A total of 16 exposed HCWs/HCSs (11 exposed HCWs/
HCSs administered 3TC/AZT for 3 days and 5 exposed
HCWs/HCSs administered 3TC/AZT for 28 days) trun-
cated their regimen schedule when the source patient
tested HIV negative. The lost to follow-up (LFU) pro-
portion among exposed HCWs/HCSs administered
3TC/AZT for 28 days was significantly lower (p < 0.001)
compared with those administered 3TC/AZT for 3 days,
Fig. 1 Algorithm used in determining the level of risk of exposures
Tetteh et al. BMC Public Health  (2015) 15:573 Page 4 of 13
but not significantly different (p = 0. 832) from exposed
HCWs/HCSs administered 3TC/AZT/LPV-RTV for 28
days. Over 80 % of the exposed HCWs/HCSs reported
their exposure within 24 h and the median time between
exposure and reporting was 2.0 h in both HCWs and
HCSs. Follow-up for HIV testing was done at 6 weeks, 3
months and 6 months after exposure/HIV PEP adminis-
tration and none of the HCWs/HCSs followed-up sero-
converted.
Table 1 show characteristics of the HCWs/HCSs admin-
istered the HIV PEP regimen. The female population
constituted 68 % (n = 99) of exposed HCWs/HCSs
administered 3TC/AZT for 3-days, 50 % (n = 41) of ex-
posed HCWs/HCSs administered 3TC/AZT for 28 days
and 53 % (n = 28) of those administered 3TC/AZT/LPV-
RTV for 28 days. The 18–30 years age category repre-
sented the largest number of HCWs/HCSs administered
all the three PEP regimens (82 % in exposed HCWs/HCSs
administered 3TC/AZT for 3-days, 60 % in exposed
HCWs/HCSs administered 3TC/AZT for 28 days and
70 % in exposed HCWs/HCSs administered 3TC/AZT/
LPV-RTV for 28 days). Whilst risk assessment results for
most of the exposed HCWs/HCSs administered 3TC/
AZT for 3-days were low (86 %, n = 125), the majority of
exposed HCWs/HCSs administered 3TC/AZT/LPV-RTV
for 28 days risk assessment results was high (83 %, n = 44).
The majority of exposed HCWs/HCSs administered 3TC/
AZT for 28 days risk assessment results were either low
risk (35 %, n = 29) or medium risk (48 %, n = 39). A vast
majority of the reported exposures in general were percu-
taneous (93 %, n = 260) with needle stick injuries being
the most reported means of exposure (85 %, n = 237).
Reporting of adverse events
Out of a total of 228 HCWs/HCSs administered HIV
PEP and followed up, 146 (64 %) reported at least one
adverse event made up of three spontaneous reports and
143 reports from active surveillance. The proportion of
those who reported at least one adverse event was
significantly higher (p < 0.001) in exposed HCWs/HCSs
administered 3TC/AZT for 28 days (n = 68, 91 %)
compared with exposed HCWs/HCSs administered
3TC/AZT for 3 days (n = 28, 28 %) but not significantly
different (p = 0.236) from exposed HCWs/HCSs admin-
istered 3TC/AZT/LPV-RTV for 28 days (n = 50, 96 %).
Table 2 shows the Cox regression analyses to deter-
mine factors associated with the occurrence of adverse
events. In the univariate analysis, gender, profession, age
category and type of exposure were not associated with
the reporting of adverse events. The outcome of the risk
assessment done prior to drug administration (low,
medium or high) was associated with adverse events in
the univariate but not associated when adjusted for
other variables in the multivariate analysis. The duration
of drug regimen administered was associated with the
reporting of adverse events in both the univariate and
multivariate analysis. For exposed HCWs/HCSs adminis-
tered the same drug regimen (3TC/AZT ) for different
durations, those administered 3TC/AZT for 3 days were
70 % less likely to report an adverse event compared
with those administered 3TC/AZT for 28 days (Adjusted
HR = 0.30 [95 % CI, 0.18-0.48], p < 0.001) (Table 2).
There was no significant difference (p = 0.817) in the
reporting of adverse events between exposed HCWs/
HCSs administered 3TC/AZT for 28 days and exposed
HCWs/HCSs administered 3TC/AZT/LPV-RTV for 28
days in the multivariate analysis.
Description of reported adverse events
The most frequently observed type of adverse event re-
ported in all the three PEP regimens was gastrointestinal in
nature (Table 3). Nausea, weakness, malaise and dizziness
(17 %, 10 %, 6 % and 6 %, respectively) were the four most-
commonly reported adverse events in exposed HCWs/
HCSs administered 3TC/AZT for 3 days. Exposed HCWs/
HCSs on 3TC/AZT for 28 days reported nausea (63 %),
Fig. 2 Distribution of exposed HCWs/HCSs administered PEP by regimen
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Table 1 Baseline characteristics of 280 HCWs/HCSs reporting occupational exposures and administered HIV post-exposure prophy-
laxis at an urban teaching hospital in Accra, Ghana, 2005–2010
3TC/AZT-3 days 3TC/AZT-28 days 3TC/AZT/LPV-RTV −28 days
N = 145 N = 82 N = 53
n, %1 n, %1 n, %1
Gender
Male 46 (31.7) 41 (50.0) 25 (47.2)
Female 99 (68.3) 41 (50.0) 28 (52.8)
Age category (yrs)
18–30 119 (82.1) 49 (59.8) 37 (69.8)
31–40 21 (14.5) 24 (29.3) 10 (18.9)
41–50 3 (2.1) 5 (6.1) 5 (9.4)
>50 2 (1.4) 4 (4.9) 1 (1.9)
Outcome of risk assessment of exposure
Low 125 (86.2) 29 (35.4) 5 (9.4)
Medium 20 (13.8) 39 (47.6) 4 (7.6)
High - 14 (17.1) 44 (83.0)
Profession
Medical Doctors 40 (27.6) 27 (32.9) 22 (41.5)
Nurses 64 (44.1) 26 (31.7) 19 (35.8)
Laboratory Staff 4 (2.8) 8 (9.8) 5 (9.4)
Ward Attendants 13 (9.0) 13 (15.9) 4 (7.5)
Healthcare Students 24 (16.6) 8 (9.8) 3 (5.7)
Type of exposure
Mucocutaneous 7 (4.8) 3 (3.7) 10 (18.9)
Percutaneous 138 (95.2) 79 (96.3) 43 (81.1)
Year of exposure
2005 26 (17.9) 14 (17.1) 12 (22.6)
2006 30 (20.7) 10 (12.2) 4 (7.5)
2007 23 (15.9) 15 (18.3) 10 (18.9)
2008 24 (16.6) 16 (19.5) 6 (11.3)
2009 27 (18.6) 15 (18.3) 15 (28.3)
2010 15 (10.3) 12 (14.6) 6 (11.3)
Means of exposure
Bloody cut 1 (0.7) 1 (1,2) 1 (1.9)
Canula 4 (2.8) 2 (2.4) 16 (30.2)
Dental instrument 1 (0.7) - -
Needle stick 133 (91.7) 77 (93.9) 27 (50.9)
Scalpel blade - 1 (1.2) 2 (3.8)
Scratching 1 (0.7) - -
Knife cut 1 (0.7) - -
Splash 2 (1.4) 1 (1.2) 7 (12.2)
Unknown object 2 (1.4) - -
1% are column percentages within each super row; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir
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weakness (37 %), fatigue (28 %) and dizziness (27 %) as
the four most reported adverse events. On the other
hand, nausea, diarrhoea, vomiting and weakness (71 %,
65 %, 35 % and 31 %, respectively) were the four most
commonly reported adverse events in exposed HCWs/
HCSs administered 3TC/AZT/LPV-RTV for 28-days.
Nausea was the most commonly reported adverse
events in all three regimens. There were a total of five
reports of rashes-two reports each in exposed HCWs/
HCSs administered 3TC/AZT for 3 days and 28 days
and one report in an exposed HCW administered 3TC/
AZT/LPV-RTV for 28 days (Table 3).
There were three spontaneous reports of adverse events
which ended up in hospitalisation but all recovered. The
first was an exposed female HCW of 26 years adminis-
tered 3TC/AZT/LPV-RTV for 28 days who reported of
dizziness, excessive flatulence, headache, nausea, vomiting,
restlessness and dark pigmentation of finger & toe nails
(which later came off) and was hospitalised for three days.
The second case which resulted in hospitalisation for
seven days involved a 29-year old exposed pregnant
female HCW (in the first trimester of pregnancy) who
reported of abdominal pains, profuse diarrhoea, fatigue,
nausea and bleeding which later resulted in spontaneous
abortion. The third case involved an exposed female
HCW of 42 years who was administered 3TC/AZT for 28
days and reported of fatigue, headache and weakness
which according to her resulted in a “near death” experi-
ence. She was hospitalised for three days. These three
serious adverse events all involving females have been
reported to the National Pharmacovigilance Centre at
Ghana’s Food and Drugs Authority.
Adherence to prophylaxis schedule
Complete adherence to PEP schedule was 77 % (n = 175)
in this study. All the 53 PEP exposed HCWs/HCSs who
Table 2 Factors associated with reported adverse events in 228 exposed HCWs/HCSs on HIV post-exposure prophylaxis
Characteristic Adverse events status1 Crude hazard







3TC/AZT −28 days 68 7 1.00 1.00
3TC/AZT-3 days 28 73 0.31 [0.20–0.48] <0.001 0.30 [0.18–0.48] <0.001
3TC/AZT/LPV-RTV-28 days 50 2 1.06 [0.74–1.53] 0.752 1.06 [0.65–1.72] 0.817
Gender -
Female 81 50 1.00
Male 65 32 1.08 [0.78–1.50] 0.629
Type of exposure -
Percutaneous 131 80 1.00
Mucocutaneous 15 2 1.42 [0.83–2.43] 0.197
Age category (yrs) -
18–30 101 60 1.00
31–40 32 18 1.02 [0.69–1.52] 0.921
41–50 8 2 1.28 [0.62–2.62] 0.508
>51 5 2 1.14 [0.46–2.80] 0.777
Risk assessment
Low 51 63 1.00 1.00
Medium 40 16 1.60 [1.06–2.42] 0.027 0.95 [0.61–1.49] 0.885
High 55 3 2.12 [1.45–3.10] <0.001 0.97 [0.57–1.66] 0.922
Profession -
Nurses 51 31 1.00
HCS 14 10 0.94 [0.52–1.69] 0.832
Laboratory Staff 15 1 1.51 [0.85–2.68] 0.162
Medical Doctors 46 31 0.96 [0.65–1.43] 0.843
Ward Attendants 20 9 1.11 [0.66–1.86] 0.695
1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16)
were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval
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Table 3 Preferred term within system organ classification of reported adverse events of 228 exposed HCWs/HCSs on HIV post-exposure
prophylaxis
Number of adverse events reported
by preferred term within system organ
classification (n, %1)
Total 3TC/AZT-3 days 3TC/AZT-28 days 33TC/AZT/LPV-RTV-28 days
N = 228 N = 101 N = 75 N = 52
n, %1, 2 n, %1, 2 n, %1, 2
Gastrointestinal (n = 122, 53.5)
Nausea 101 (44.3) 17 (16.8) 47 (62.7) 37 (71.2)
Diarrhoea 38 (16.7) 3 (3.0) 1 (1.3) 34 (65.4)
Vomiting 24 (10.5) 1 (1.0) 5 (6.7) 18 (34.6)
Loss of appetite 14 (6.1) 3 (3.0) 6 (8.0) 5 (9.6)
Abdominal pains 14 (6.1) 2 (2.0) 5 (6.7) 7 (13.5)
Anorexia 5 (2.2) - 2 (2.7) 3 (5.8)
Dehydration 1 (0.4) - 1 (1.3) -
Bitter mouth 1 (0.4) 1 (1.0) - -
Constipation 1 (0.4) - 1 (1.3) -
Excessive flatulence 1 (0.4) - - 1 (1.9)
Abdominal discomfort 1 (0.4) - 1 (1.3) -
Hyper-salivation 1 (0.4) - - 1 (1.9)
Sore throat 1 (0.4) - - 1 (1.9)
Excessive spitting 1 (0.4) - 1 (1.3) -
Hunger pain 1 (0.4) - 1 (1.3) -
Systematic signs & symptoms (n = 106, 46.5)
Weakness 54 (23.7) 10 (9.9) 28 (37.3) 16 (30.8)
Malaise 37 (16.2) 6 (5.9) 17 (22.7) 14 (26.9)
Dizziness 30 (13.2) 6 (5.9) 20 (26.7) 4 (7.7)
Fatigue 28 (12.3) 2 (2.0) 21 (28.0) 5 (9.6)
Feverish 5 (2.2) - 2 (2.7) 3 (5.8)
General body pains 2 (0.9) - 2 (2.7) -
Neurological system (n = 42, 18.4)
Headache 27 (11.8) 3 (3.0) 19 (25.3) 5 (9.6)
Restlessness 8 (3.5) 2 (2.0) 4 (5.3) 2 (3.8)
Insomnia 7 (3.1) 1 (1.0) 4 (5.3) 2 (3.8)
Drowsiness 5 (2.2) 1 (1.0) 1 (1.3) 3 (5.8)
Depression 1 (0.4) - 1 (1.3) -
Skin (n = 9, 3.9)
Rashes 5 (2.2) 2 (2.0) 2 (2.7) 1 (1.9)
Itching 2 (0.9) 2 (2.0) - -
Alopecia 1 (0.4) - 1 (1.3) -
Dark pigmentation of finger & toe nails 1 (0.4) - - 1 (1.9)
Central/peripheral nervous system (n = 4, 1.8)
Eye pain 1 (0.4) - 1 (1.3) -
Leg pains 1 (0.4) - 1 (1.3) -
Neck pains 1 (0.4) - - 1 (1.9)
Pain in feet 1 (0.4) - - 1 (1.9)
Red eye 1 (0.4) - - 1 (1.9)
Hepatitis (n = 2, 0.9)
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defaulted in their 28-days prophylaxis schedule did so
within 14 days of medication initiation. None of the
exposed HCWs/HCSs on the 3-day schedule defaulted in
medication adherence. Comparing the different PEP regi-
mens administered, adherence to the prophylaxis schedule
was significantly higher (p < 0.001) in exposed HCWs/
HCSs administered 3TC/AZT for 3-days (100 %, n = 101)
compared with exposed HCWs/HCSs administered 3TC/
AZT for 28-days (56.0 %, n = 42) and exposed HCWs/
HCSs administered 3TC/AZT/LPV-RTV for 28-days
Table 3 Preferred term within system organ classification of reported adverse events of 228 exposed HCWs/HCSs on HIV post-exposure
prophylaxis (Continued)
Yellow eyes 1 (0.4) - 1 (1.3) -
Jaundice 1 (0.4) - - 1 (1.9)
Cardiac (n = 1, 0.4)
Tightness in chest 1 (0.4) - 1 (1.3) -
Reproductive/gynaecological (n = 1, 0.4)
Spontaneous abortion 1 (0.4) - - 1 (1.9)
Bleeding 1 (0.4) - - 1 (1.9)
1Percentages may add up to >100
2% are percentages within each drug column; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir
Table 4 Factors associated with adherence in exposed HCWs/HCSs on HIV post-exposure prophylaxis
Characteristic Adherence Status1 Crude hazard







3TC/AZT −28 days 42 33 1.00 1.00
3TC/AZT-3 days 101 0 1.79 [1.25–2.56] 0.002 1.75 [1.16–2.66] 0.008
3TC/AZT/LPV-RTV −28 days 32 20 1.10 [0.69–1.74] 0.688 1.02 [0.56–1.88] 0.938
Gender
Female 102 29 1.00
Male 73 24 0.97 [0.72–1.31] 0.824 - -
Age range (years)
18–30 129 32 1.00
31–40 34 16 0.85 [0.58–1.24] 0.395
41–50 6 4 0.75 [0.33–1.70] 0.489
>51 6 1 1.07 [0.47–2.43] 0.872 - -
Risk assessment
Low 103 11 1.00 1.00
Medium 36 20 0.71 [0.49–1.04] 0.079 0.91 [0.60–1.39] 0.672
High 36 22 0.69 [0.47–1.00] 0.052 1.05 [0.56–2.00] 0.871
Type of exposure
Percutaneous 165 46 1.00
Mucocutaneous 10 7 0.75 [0.40–1.42] 0.382 - -
Profession
Nurses 65 17 1.00
HCS 19 5 1.00 [0.60–1.67] 0.996
Laboratory Staff 9 7 0.71 [0.35–1.43] 0.335
Medical Doctors 59 18 0.97 [0.68–1.38] 0.850
Ward Attendants 23 6 1.00 [0.62–1.61] 0.998 - -
1N = 228, exposed HCWs/HCSs lost to follow (n = 36) and exposed HCWs/HCSs who truncated their schedule due to source patient testing HIV negative (n = 16)
were excluded; 3TC = lamivudine; AZT = zidovudine; LPV-RTV = lopinavir-ritonavir; CI = confidence interval
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(61.5 %, n = 32). However, there was no statistical differ-
ence (p = 0. 534) in adherence proportion between ex-
posed HCWs/HCSs administered 3TC/AZT for 28-days
and exposed HCWs/HCSs administered 3TC/AZT/LPV-
RTV for 28-days.
Table 4 shows the factors associated with adherence in
both the univariate and multivariate Cox regression ana-
lysis. Gender, profession, outcome of risk assessment,
type of exposure and age category was not associated
with adherence in the univariate analysis. For the same
drug regimen exposed HCWs/HCSs administered 3TC/
AZT for 3-days were 75 % more likely to adhere to the
schedule compared with exposed HCWs/HCSs adminis-
tered 3TC/AZT for 28-days (Adjusted HR = 1.75 [95 %
CI, 1.16-2.66], p = 0.008). There was no statistical signifi-
cant difference in terms of adherence between exposed
HCWs/HCSs administered 3TC/AZT for 28 days and
exposed HCWs/HCSs administered 3TC/AZT/LPV-
RTV for 28 days (p = 0.660).
In a separate analysis to determine the association
between the two study outcomes (report of adverse
events and adherence), exposed HCWs/HCSs who never
reported of adverse events were 57 % more likely to
adhere to their medication schedule compared with
exposed HCWs/HCSs who reported of at least one ad-
verse event (HR = 1.57 [95 % CI, 1.17-2.11], p = 0.003).
All the 53 exposed HCWs/HCSs who did not adhere
completely to their PEP medication schedule cited
adverse events as their reason for non-adherence.
Discussion
The findings provide insight into the occurrence of
adverse events and adherence to medication schedule in
HIV negative HCWs/HCSs who presented for PEP at
the KBTH between January 2005 and December 2010.
The present results show that adverse events are very
common (1 in 10) in exposed HCWs/HCSs undergoing
different regimens, more so with the 28-day regimens.
Again, it showed that serious adverse events leading to
hospitalization were common, occurring in this case at a
frequency higher than 1 in 100 (3 serious adverse events
in 228 exposed HCWs/HCSs). All the exposed HCWs/
HCSs who reported serious adverse events were females
and were on 28 days regimen schedule. The importance
of the duration of treatment on adverse events and ad-
herence is starkly demonstrated by the fact that adverse
events were low and adherence excellent in the 3 days
regimen schedule whilst adverse events were more com-
mon and adherence varied between 56 and 62 % in the
28 days regimen schedule.
In this study exposed HCWs/HCSs administered PEP
were allowed to describe their complaints in their own
context before the use of the system organ class (SOC)
classification to group the adverse events reported. In
general, these exposed HCWs/HCSs administered PEP
were not on other medications of note and therefore
related these events to the anti-retroviral medications
administered. The events reported did not exist prior to
initiation of therapy. The present results indicate an
overall adverse event frequency of 64 %, which is lower
than the results of other studies where the frequency of
adverse events was reported to be between 70 and 76 %
[15, 18, 26]. However the reported high adverse events
frequency of 96 % in exposed HCWs/HCSs administered
3TC/AZT/LPV-RTV (triple therapy) for 28 days is com-
parable to reported adverse events frequency of also
96 % in PEP patients administered the same regimen of
3TC/AZT/LPV-RTV for 28 days in sexual assault survi-
vors [27].
As expected, the adverse events reported were consist-
ent with the product profiles (Summary of Product
Characteristics-SmPC) of the PEP medications in use.
The most frequently cited symptoms were gastrointes-
tinal in nature; vomiting, diarrhoea, and nausea followed
by neurological symptoms like headache, weakness and
fatigue which is similar to results from other PEP studies
[15, 18, 19, 28].
The study recorded three serious adverse events – all
cases of hospitalisations following initiation of PEP.
Worth noting was the case of dark pigmentation (hyper
pigmentation) of finger and toe nails reported by a pa-
tient on 3TC/AZT/LPV-RTV for 28 days which inciden-
tally has been reported in some other studies as a
cutaneous adverse reaction of zidovudine (AZT), mostly
in patients on chronic treatment of HIV [28]. The case
of spontaneous miscarriage was recorded in a patient in
the first trimester of pregnancy. The three anti-retroviral
drugs involved (3TC/AZT/LPV-RTV) are classified as
pregnancy category “C” and were used in as the benefits
of the combination appeared to outweigh any potential
risks. Whilst other causes for spontaneous abortion
could not be ruled out in this patient, the occurrence of
this event following intake of 3TC/AZT/LPV-RTV ne-
cessitates constant vigilance on the relationship between
pregnancy outcomes and intake of the combination in
order to generate enough evidence to support its contin-
ual use in pregnancy, especially during the first trimester
whether used for PEP or for HAART. Both cases were
also associated with severe diarrhoea and vomiting and
the subjects were rehydrated, stabilized and discharged,
with appropriate counselling to continue and complete
the course of 28 days since their risk assessment were
rated high. The third case of serious adverse event of
fatigue, headache and weakness involving an exposed
female HCW of 42 years was also stabilized and dis-
charged (after three days hospitalisation) with appropri-
ate counselling to continue and complete the course of
28 days.
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This study could not establish any association between
the report of at least one adverse events and factors such
as gender, age, profession, outcome of risk assessment
and type of exposure in the multivariate analysis al-
though other studies have associated adverse events with
gender [17]. The present results showed that for the
same type of drug regimen (dual therapy) administered
as PEP, exposed HCWs/HCSs on the longer schedule
(28 days) experienced more adverse than and were more
likely to be non-adherent to treatment than those on
shorter schedules. Even though other studies have shown
an association of more frequent adverse events with triple
therapy compared with dual therapy [1, 15, 21, 22], the
present results rather indicate that the association may be
due to the duration of therapy since there was no difference
in frequency of adverse events when both the dual therapy
(3TC/AZT) and triple therapy (3TC/AZT/LPV-RTV) were
administered for 28 days. The association of longer dur-
ation of prophylaxis (28-days) to the reporting of adverse
events may be due to the time to onset of adverse events as
studies [15, 18] have shown adverse events to begin to
appear from the fourth day of drug administration.
Results from this study indicate an overall adherence
rate of 77 %. Although this adherence rate is far higher
than reported in some studies [15, 26], it is comparable
to other reports [19, 29]. Similar to the adverse events
reportage, shorter therapy schedules of 3 days were asso-
ciated with better (excellent in this study) adherence
compared with the longer duration of 28 days. It has
been shown that knowledge and proper communication
of expected side effects of ARVs in patients leads to
increased rate of adherence to the treatment [30]. The
possibility of receiving either dual or triple therapy for
28 days depends on the outcome of the risk assessment
which leaves no choice for the exposed HCW/HCS. Edu-
cation and counselling are therefore very important in en-
suring maximum adherence. The intolerability to adverse
events was cited as the sole reason for truncating PEP,
thereby indicating the need for adequate, appropriate and
effective counselling, education, active follow-up (possibly
through mobile/phone contact) and management of ad-
verse events. Education on the need to complete PEP
schedule (especially for exposed HCWs/HCSs on 28-day
schedule) can lead to increased adherence which is very
critical in preventing HIV sero-conversion. This may also
reduce anxieties associated with the injuries. In addition,
the need for monitoring and managing of adverse events
may encourage completion of PEP schedule by HCWs
who are exposed [31].
The use of the CEM technique in this study has led to
the successful monitoring of adverse events and adher-
ence to PEP schedule. This study has demonstrated that
is it possible to effectively conduct an active safety moni-
toring of ARVs used in PEP in resource limited settings
like the KBTH in Accra, Ghana. The safety data ob-
tained from this CEM study are consistent with the
safety profile expected for the medicines concerned.
Since the tendency to passively/spontaneously report
adverse events and adherence in HIV negative exposed
HCWs/HCSs on PEP is generally low, CEM will become
a key pharmacovigilance method in resource-limited
settings due to its ability to aid in rapid identification of
signals and to effectively compare regimen and the effect
of treatment type and duration on both adverse events
and adherence.
Most of the exposed HCWs/HCSs were willing to be
followed up by phone and loss to follow up was reason-
ably low compared to other studies in these settings. Al-
though the inability to follow exposed HCWs/HCSs
administered PEP beyond 6 months to monitor possible
long term toxicities is a limitation, monitoring of long
term toxicities was not the focus of the current study.
Since laboratory tests for liver enzymes, full blood count,
etc. were not conducted, it is not known to what extent
the medicines might have caused abnormalities which
could only be detected via laboratory testing. However
the relatively shorter period of 28 days given for PEP
does not permit extrapolation of data to the identifica-
tion of possible long-term toxicities that might have oc-
curred if these products had been taken for long periods.
The results cannot therefore be extrapolated to verify or
refute known HAART induced toxicities like hepatitis or
zidovudine-induced anaemia [32] which occur during
the initial months of therapy in HIV-positive patients.
Despite this, intensive laboratory monitoring during the
period PEP should be encouraged and facilitated to iden-
tify all toxicities.
Although the results of this study cannot be necessarily
generalized across HIV/AIDS treatment sites in Ghana or
in West Africa and other resource-limited settings, the in-
cidence of adverse events and non-adherence provides an
insight into what to expect in such settings and this infor-
mation could be used for patient education and the educa-
tion of HCWs as PEP provision is scaled up. This study
has shown the importance of focused cohort studies in
generating important safety information in resource-
limited settings where the spontaneous reporting ADR
systems yield very little data and where healthcare systems
e.g. absence of electronic health records and weak labora-
tory infrastructure, do not permit collection of safety data
in any systematic manner. A possible limitation of the
current study is the in-house medication adherence met-
rics used. Although medication adherence metrics are
available including the one validated by Morisky et al.
[33], none was used in this HIV PEP situation where ex-
posed HCWs/HCSs may take the prophylactic medication
for a maximum of 28 days. There is therefore the need to
develop specific tools for measuring medication adherence
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in PEP whether short (3 days) or long (28 days) treatment
periods are chosen.
Conclusions
In conclusion, it is possible to use active follow-up method
via mobile phone calls to monitor both adverse events and
adherence to prophylaxis regimen in HIV-negative PEP
subjects. The study showed that adverse events to PEP are
very common and could be severe or serious requiring
hospitalization for management in some cases and that
the nature and frequency of adverse events collected in
the current study were consistent with available informa-
tion on the use of those antiretroviral drugs. Much em-
phasis should be attached to follow-ups in order to advise
and act promptly when issues arise. This study also indi-
cated the need for education of exposed HCWs/HCSs on
the importance of complete adherence to HIV PEP in
order to minimize the risk of HIV sero-conversion.
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